Introduction {#section5-1758835920929583}
============

In the past 10 years, an unprecedented revolution in the treatment landscape for metastatic melanoma has yielded continuously improving survival outcomes for these patients.^[@bibr1-1758835920929583]^ Before 2011, metastatic melanoma was associated with devastating outcomes, with a median overall survival (OS) of approximately 9 months and 3-year OS of approximately 12%.^[@bibr2-1758835920929583]^ However, the identification of negative immune checkpoints \[cytotoxic T-lymphocyte associated protein 4 (CTLA-4) or programmed cell death 1 (PD-1)\]^[@bibr3-1758835920929583],[@bibr4-1758835920929583]^ has tremendously changed the standards of clinical performance for therapies for this disease. Since the regulatory approval of a CTLA-4 inhibitor (ipilimumab) by the US Food and Drug Administration (FDA), 3-year OS of treated patients has increased to 30%.^[@bibr2-1758835920929583],[@bibr5-1758835920929583]^ Currently, other newer agents that block the binding of PD-1 to its ligand, programmed death ligand 1 (PD-L1), within the cancer microenvironment have attracted more interest from oncology researchers. Notably, several clinical trials demonstrated that, compared with ipilimumab monotherapy alone, anti-PD-1/PD-L1 therapy with or without ipilimumab further improved the survival of patients with metastatic melanoma, leading to 4-year OS of 53% and 46%, respectively.^[@bibr5-1758835920929583][@bibr6-1758835920929583]--[@bibr7-1758835920929583]^

The rapid advances in anti-PD-1/PD-L1 therapy for melanoma has spurred researchers and physicians to explore more effective therapies to further extend the clinical benefit; however, a critical issue that is still under investigation is what is the optimal endpoint and how should tumour response be evaluated in anti-PD-1/PD-L1 trials for metastatic melanoma. In conventional randomized clinical trials of melanoma, OS is considered the gold standard for the endpoint because it is simple to measure, easy to interpret, and unbiased. However, of the use of OS requires prolonged follow-up durations and larger sample sizes to detect statistically significant differences, consideration of the effect of subsequent therapies after progression that might prolong survival, and the risk of noncancer deaths. Therefore, reliable endpoints that could be used as surrogates for OS in metastatic melanoma could shorten the follow-up period and reduce the cost of drug development. A previous meta-analysis reported that progression-free survival (PFS) could be considered a valid surrogate for OS in dacarbazine-controlled randomized trials of metastatic melanoma.^[@bibr8-1758835920929583]^ Nonetheless, in the era of immunotherapy, PD-1/PD-L1 inhibitors rather than dacarbazine are assigned as the control arm, and the mechanisms of action of anti-PD-1/PD-L1 agents are markedly distinct from those of cytotoxic agents; there is delayed antitumour activity,^[@bibr9-1758835920929583]^ pseudoprogression^[@bibr10-1758835920929583]^ and hyperprogressive disease^[@bibr11-1758835920929583]^ during anti-PD-1/PD-L1 therapy. Therefore, it is still uncertain whether PFS or other Response Evaluation Criteria in Solid Tumors (RECIST) criteria-defined endpoints \[including objective response rate (ORR) and disease control rate (DCR)\] can sufficiently reflect the antitumour effect of these drugs in melanoma.

Based on this premise, we performed this meta-analysis to assess the correlation between PFS, ORR, DCR and OS in trials of anti-PD-1/PD-L1 drugs for metastatic melanoma.

Methods {#section6-1758835920929583}
=======

Search strategy and selection criteria {#section7-1758835920929583}
--------------------------------------

In June 2019, we systematically searched the Medline (PubMed), Embase, ClinicalTrials.gov and Cochrane Library databases. We also manually searched the references of the included trials and abstracts of two conference proceedings \[the 2019 American Society of Clinical Oncology (ASCO) annual meeting and the European Society for Medical Oncology (ESMO) 2018 congress\] to retrieve additional studies. We searched for the following concepts and linked them together with the AND operator: 'nivolumab', 'pembrolizumab', 'avelumab', 'atezolizumab', 'durvalumab', 'PD-1', 'PD-L1', 'checkpoint inhibitors', 'melanoma' and 'randomized controlled trial' ([Box 1, Supplemental materials](http://journals.sagepub.com/doi/suppl/10.1177/1758835920929583)).

We included phase II or phase III trials of unresectable, advanced or recurrent melanoma that used PD-1/PD-L1 inhibitors in the experimental arm and any therapy in the control arm. We required trials to report the hazard ratios (HRs) for OS and PFS and/or odds ratios (ORs) for ORR and DCR. We excluded reviews, abstracts, case reports, studies that were not published as full-text articles and studies with cohorts of less than 50 patients. Two authors (RCN and SQY) extracted the following characteristics for each trial: population, study phase, experiment arm, control arm, number of patients, primary endpoint, crossover, follow-up period, OS results and surrogate endpoints (PFS, ORR and DCR). Discrepancies in the literature search and data extraction were resolved by two senior authors (ZWZ and YFL).

Endpoint definitions {#section8-1758835920929583}
--------------------

OS was defined as the time from randomization to death from any cause. PFS was defined as the time from randomization to progressive disease or death from any cause. ORR was defined as the proportion of confirmed complete response (CR) or partial response (PR) at the point of best overall response. DCR was defined as the percentage of confirmed CR, PR or stable disease at the point of best overall response.

Statistical analysis {#section9-1758835920929583}
--------------------

We assessed the correlation between the treatment effect (HR or OR) among the surrogate endpoints (PFS, ORR, and DCR) and OS using a linear regression model.^[@bibr12-1758835920929583]^ To interpret the differences between studies with respect to study size and precision of HR estimates, we weighted the analysis proportionally to the study sample size or to the precision of the observed treatment effects. Hence, we used a fixed effect model and a random effect model as the weighting strategies.^[@bibr13-1758835920929583]^ While the fixed effect meta-analysis is based on the presumption that a common treatment effect exists among every trial and uses the estimated inverse variance as weights, the random effect meta-analysis permits treatment effect discrepancy from trial to trial and merges the potential among-trial variation of effects into the weights. Overall, we applied three weighting strategies (sample size, fixed effect and random effect). According to A'Hern *et al.*,^[@bibr14-1758835920929583]^ we downweighted the sample size if trials reported more than two treatment arms.

We calculated the weighted coefficient of determination (*R*^2^) to quantify the variation explained by the surrogate endpoints. We considered the correlation between OS and surrogate endpoints to be strong if the *R*^2^ exceeded 0.75.^[@bibr15-1758835920929583],[@bibr16-1758835920929583]^ The surrogate threshold effect (STE),^[@bibr16-1758835920929583]^ defined as the minimum treatment effect on the surrogate necessary to predict a nonzero effect on the OS, was calculated. For future trials, the upper limit of the confidence interval (CI) for the estimated surrogate treatment effect should fall below the STE to predict a nonzero effect on OS. The STE in this study were performed through sample size weighting strategy.

Since the estimated treatment effect of OS can be influenced by crossover design, sample size and other potential factors, we performed several sensitivity analyses that restricted the analyses to trials with crossover \<50%, phase III trials, large trials (comparisons with \>300 patients) trials, and trials with first-line therapy. For each meta-analysis, we applied an internal validation through leave-one-out analysis to evaluate the prediction accuracy of the surrogate model.^[@bibr17-1758835920929583]^ Each trial was left out once, and the surrogate model was built with other trials. This model was then re-applied to the left-out trial, and a 95% prediction interval was calculated to compare the predicted and observed treatment effect on OS. All statistical analyses were performed using R version 3.6.0 (<http://www.r-project.org>).

Results {#section10-1758835920929583}
=======

After systematically screening 254 relevant articles ([Figure 1](#fig1-1758835920929583){ref-type="fig"}), we identified eight trials (three phase II trials and five phase III trials) comprising 4110 subjects that were eligible for inclusion.^[@bibr5-1758835920929583][@bibr6-1758835920929583]--[@bibr7-1758835920929583],[@bibr18-1758835920929583][@bibr19-1758835920929583][@bibr20-1758835920929583][@bibr21-1758835920929583]--[@bibr22-1758835920929583]^ [Table 1](#table1-1758835920929583){ref-type="table"} shows detailed information from the included trials. The median follow-up duration of the included trials varied from 9.6 months to 46.9 months. We noted that three trials had three treatment arms.^[@bibr5-1758835920929583],[@bibr7-1758835920929583],[@bibr18-1758835920929583]^ In order to avoid the over-fitting correlation, we excluded the comparisons of pembrolizumab 10 mg/kg *versus* pembrolizumab 2 mg/kg in the KEYNOTE 002 trial, pembrolizumab every 3 weeks *versus* pembrolizumab every 2 weeks in the KEYNOTE 006 trial, and nivolumab plus ipilimumab *versus* nivolumab in the CheckMate 067 trial. Therefore, all the trials included 11 comparisons for quantitative analysis. Six comparisons reported improvement in OS (upper limit of CI for HR \< 1.0), and eight comparisons reported improvement in PFS.

![Study flow diagram of the included studies in this meta-analysis.\
DCR, disease control rate; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.](10.1177_1758835920929583-fig1){#fig1-1758835920929583}

###### 

Characteristics of the included trials.

![](10.1177_1758835920929583-table1)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Studies                                                        Population                                                                                                                                     Study phase   Experimental arm                            Control arm                           *n*   Primary endpoint                                             Crossover   Median follow-up (months)
  -------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------- ------------- ------------------------------------------- ------------------------------------- ----- ------------------------------------------------------------ ----------- ---------------------------------------------
  Hodi *et al*.,^[@bibr6-1758835920929583]^ CheckMate 069        Histologically confirmed, unresectable\                                                                                                        II            Nivolumab plus ipilimumab                   Ipilimumab                            142   ORR^[a](#table-fn2-1758835920929583){ref-type="table-fn"}^   57%         24.5 months
                                                                 stage III or IV metastatic melanoma                                                                                                                                                                                                                                                                                           

  Hamid *et al*.,^[@bibr18-1758835920929583]^ KEYNOTE 002        Advanced melanoma with progression after two or more ipilimumab doses, previous BRAF or MEK inhibitor or both, if BRAF^V600^ mutant-positive   II            Pembrolizumab 2 mg/kg;\                     ICC                                   540   OS, PFS                                                      55%         28.0 months
                                                                                                                                                                                                                              Pembrolizumab 10 mg/kg                                                                                                                                           

  Schachter *et al*.,^[@bibr7-1758835920929583]^ KEYNOTE 006     Ipilimumab-naive unresectable or advanced melanoma; \<1 prior therapy;                                                                         III           Pembrolizumab every 2 weeks;\               Ipilimumab                            834   PFS, OS                                                      30%         22.9 months
                                                                                                                                                                                                                              Pembrolizumab every 3 weeks                                                                                                                                      

  Ascierto *et al*.,^[@bibr19-1758835920929583]^ CheckMate 066   Unresectable previously untreated stage III or IV melanoma, without a BRAF mutation                                                            III           Nivolumab                                   Dacarbazine                           418   OS                                                           0%          38.4 months for nivolumab, and\
                                                                                                                                                                                                                                                                                                                                                                                               38.5 months for dacarbazine

  Hodi *et al*.,^[@bibr5-1758835920929583]^ CheckMate 067        Untreated, unresectable stage III or IV melanoma, known BRAF^V600^ mutation status                                                             III           Nivolumab\                                  Ipilimumab                            945   PFS, OS                                                      0%          46.9 months for nivolumab plus ipilimumab,\
                                                                                                                                                                                                                              plus ipilimumab;\                                                                                                                                                36.0 months for nivolumab, and\
                                                                                                                                                                                                                              Nivolumab                                                                                                                                                        18.6 months for ipilimumab

  Larkin *et al*.,^[@bibr20-1758835920929583]^ CheckMate 037     Unresectable stage IIIC or IV metastatic melanoma                                                                                              III           Nivolumab                                   ICC                                   405   ORR, OS                                                      23.33%      24 months

  Long *et al*.,^[@bibr22-1758835920929583]^ KEYNOTE 022         Untreated, unresectable stage III or IV melanoma, known BRAF^V600^ mutation status                                                             III           Pembrolizumab plus epacadostat              Pembrolizumab plus placebo            706   PFS, OS                                                      0%          12·4 months

  Ascierto *et al*.,^[@bibr21-1758835920929583]^ KEYNOTE 252     Unresectable stage III or metastatic\                                                                                                          II            Dabrafenib, trametinib plus pembrolizumab   Dabrafenib, trametinib plus placebo   120   PFS                                                          0%          9.6 months
                                                                 stage IV melanoma                                                                                                                                                                                                                                                                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ICC, investigator's choice-chemotherapy; NR, not reached; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.

ORR for BRAF ^V600^ wild type.

We first derived the degree of association between potential endpoints and OS through three weighting strategies. As shown in [Table 2](#table2-1758835920929583){ref-type="table"}, we observed that the correlations between ORR (sample size: 0.25, 95% CI --0.01 to 0.99; fixed effect: 0.10, --0.09 to 0.88; random effect: 0.09, --0.10 to 0.86; [Supplemental Figure S1A](http://journals.sagepub.com/doi/suppl/10.1177/1758835920929583)), DCR (sample size: 0.57, 0.11--0.99; fixed effect: 0.44, 0.03--0.99; random effect: 0.42, 0.02--0.99; [Supplemental Figure S1B](http://journals.sagepub.com/doi/suppl/10.1177/1758835920929583)) and OS were not strong enough to support the robust surrogacy of DCR or ORR for OS. Thus, we then focused on the potential surrogacy of PFS for OS and plotted the HRs for PFS and OS ([Figure 2A](#fig2-1758835920929583){ref-type="fig"}). Deducing the correlation coefficient by weighting for sample size, we noted a strong correlation between PFS and OS (0.82, 0.41--0.99; [Table 2](#table2-1758835920929583){ref-type="table"}). While presuming no difference between therapy type and treatment effect on PFS and OS (fixed effect model) slightly weakened the degree of association (0.75, 0.30--0.99), allowing for different therapy types to have a differential effect on PFS and OS (random effect model) weakened the association (0.72, 0.25--0.99).

###### 

Correlation analysis between surrogate endpoints and OS.

![](10.1177_1758835920929583-table2)

  Surrogate endpoint   Weighted coefficient of determination, *R*^2^ (95% CI)   *p* value
  -------------------- -------------------------------------------------------- -----------
  **DCR**                                                                       
   Sample size         0.57 (0.11--0.99)                                        0.007
   Fixed effect        0.44 (0.03--0.99)                                        0.024
   Random effect       0.42 (0.02--0.99)                                        0.031
  **ORR**                                                                       
   Sample size         0.25 (--0.01 to 0.99)                                    0.118
   Fixed effect        0.10 (--0.09 to 0.88)                                    0.338
   Random effect       0.09 (--0.10 to 0.86)                                    0.360
  **PFS**                                                                       
   Sample size         0.82 (0.41--0.99)                                        \<0.001
   Fixed effect        0.75 (0.30--0.99)                                        \<0.001
   Random effect       0.72 (0.25--0.99)                                        \<0.001

CI, confidence interval; DCR, disease control rate; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.

![Correlation between treatment effects on overall survival and progression-free survival. Each trial is represented by a circle, with the size of the circle being proportional to the sample size. (A) The blue line represents the 95% prediction limit of the regression line (red line). Model equation: HR ~OS~ = 0.215 + 0.845×HR ~PFS~, *R*2 ~sample\ size~ = 0.82 with *p* \< 0.001, STE = 0.78; (B) Crossover \<50% (blue hollow rectangle; *R*2 ~sample\ size~ = 0.94 with *p* \< 0.001) *versus* ⩾50% (red hollow circle; *R*2 ~sample\ size~ = 0.76 with *p* = 0.329).\
HR, hazard ratio; OS, overall survival; PFS, progression-free survival; STE, surrogate threshold effect.](10.1177_1758835920929583-fig2){#fig2-1758835920929583}

HR ~OS~ = 0.215 + 0.845 × HR ~PFS~, where HR ~PFS~ represents the HR for PFS and HR ~OS~ represents the predicted HR for OS. This model indicates that every 1% PFS risk reduction due to anti-PD-1/PD-L1 treatment can induce 0.845% risk reduction of OS. We then calculated the STE of 0.78, indicating that a future anti-PD-1/PD-L1 trial would need less than 0.78 for PFS of the upper limit of the confidence interval to predict an OS benefit ([Figure 2A](#fig2-1758835920929583){ref-type="fig"}).

There may have been potential heterogeneity due to the crossover effects and sample size; in our study, we noted two outliers in the plot of the HRs for PFS and OS ([Figure 2A](#fig2-1758835920929583){ref-type="fig"}). We observed that these two outliers were mainly from two comparisons of the studies of Checkmate 069^6^ and KEYNOTE 002.^[@bibr18-1758835920929583]^ Notably, these two studies had the similar feature: phase II designs with obvious crossover (55% and 57%, respectively), thus resulting in the discordant change between PFS and OS. Hence, we performed several sensitivity analyses ([Table 3](#table3-1758835920929583){ref-type="table"}) and noted that restriction of the analysis to eight comparisons with crossover rates less than 50% (0.94--0.94; [Figure 2B](#fig2-1758835920929583){ref-type="fig"}, [Supplemental Figure S2A](http://journals.sagepub.com/doi/suppl/10.1177/1758835920929583)) demonstrated a perfect correlation between treatment effect on PFS and OS; the three comparisons with crossover rate \>50% indicated a weakened correlation between treatment effect on PFS and OS (*R*2 = 0.76 for sample size weighting, *p* = 0.329; [Figure 2B](#fig2-1758835920929583){ref-type="fig"}). Then, we included phase III trials; the degree of association between PFS and OS was based on seven comparisons of five trials, excluding the four comparisons from the CheckMate 069,^[@bibr6-1758835920929583]^ KEYNOTE 002^18^ and KEYNOTE 252^21^ studies, and included data from 3308 subjects. An extreme strong correlation (0.94 to 0.95) between PFS and OS was noted upon restriction to phase III trials ([Table 3](#table3-1758835920929583){ref-type="table"}; [Supplemental Figure S2B](http://journals.sagepub.com/doi/suppl/10.1177/1758835920929583)). In addition, we also performed other sensitivity analyses that restricted analyses to large trials and trials on first-line treatment; all these analyses exhibited strong to very strong correlations (0.78--0.91) between PFS and OS ([Table 3](#table3-1758835920929583){ref-type="table"}; [Supplemental Figure S2C--D](http://journals.sagepub.com/doi/suppl/10.1177/1758835920929583)).

###### 

Sensitivity analysis of the correlation between PFS and OS.

![](10.1177_1758835920929583-table3)

                                                                                                                                                                                                                                              Weighted coefficient of determination, *R*^2^ (95% CI)   STE
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------- ------
  **Total population** ^[@bibr5-1758835920929583][@bibr6-1758835920929583]--[@bibr7-1758835920929583],[@bibr18-1758835920929583][@bibr19-1758835920929583][@bibr20-1758835920929583][@bibr21-1758835920929583]--[@bibr22-1758835920929583]^                                                            0.78
   Sample size                                                                                                                                                                                                                                0.82 (0.41--0.99)                                        
   Fixed effect                                                                                                                                                                                                                               0.75 (0.30--0.99)                                        
   Random effect                                                                                                                                                                                                                              0.72 (0.25--0.99)                                        
  **Trials with \<50% crossover** ^[@bibr5-1758835920929583],[@bibr7-1758835920929583],[@bibr19-1758835920929583][@bibr20-1758835920929583][@bibr21-1758835920929583]--[@bibr22-1758835920929583]^                                                                                                     0.82
   Sample size                                                                                                                                                                                                                                0.94 (0.60--0.99)                                        
   Fixed effect                                                                                                                                                                                                                               0.94 (0.58--0.99)                                        
   Random effect                                                                                                                                                                                                                              0.94 (0.58--0.99)                                        
  **Phase III trials** ^[@bibr5-1758835920929583],[@bibr7-1758835920929583],[@bibr19-1758835920929583],[@bibr20-1758835920929583],[@bibr22-1758835920929583]^                                                                                                                                          0.79
   Sample size                                                                                                                                                                                                                                0.95 (0.64--0.99)                                        
   Fixed effect                                                                                                                                                                                                                               0.94 (0.63--0.99)                                        
   Random effect                                                                                                                                                                                                                              0.94 (0.63--0.99)                                        
  **Comparisons with \>300 patients** ^[@bibr5-1758835920929583],[@bibr7-1758835920929583],[@bibr18-1758835920929583][@bibr19-1758835920929583]--[@bibr20-1758835920929583],[@bibr22-1758835920929583]^                                                                                                0.78
   Sample size                                                                                                                                                                                                                                0.86 (0.43--0.99)                                        
   Fixed effect                                                                                                                                                                                                                               0.78 (0.29--0.99)                                        
   Random effect                                                                                                                                                                                                                              0.78 (0.29--0.99)                                        
  **Trials on first-line treatment** ^[@bibr5-1758835920929583][@bibr6-1758835920929583]--[@bibr7-1758835920929583],[@bibr19-1758835920929583],[@bibr21-1758835920929583],[@bibr22-1758835920929583]^                                                                                                  0.76
   Sample size                                                                                                                                                                                                                                0.91 (0.51--0.99)                                        
   Fixed effect                                                                                                                                                                                                                               0.90 (0.49--0.99)                                        
   Random effect                                                                                                                                                                                                                              0.83 (0.34--0.99)                                        

CI, confidence interval; OS, overall survival; PFS, progression-free survival; STE, surrogate threshold effect.

The STE in this study were performed through sample size weighting strategy.

Finally, we performed a leave-one-out cross validation approach to assess the accuracy of PFS in predicting OS. We noted that the observed HR for OS fell between the limits of the 95% prediction intervals in all the 11 comparisons, indicating that the treatment effect on PFS is a valid predictor of OS ([Figure 3](#fig3-1758835920929583){ref-type="fig"}).

![Leave-one-out cross-validation analysis of the prediction of OS by treatment effect on PFS: observed HR for OS for left-out trial *versus* predicted HR for OS and 95% prediction interval for predicted HR for OS. To assess model accuracy, a leave-one-out cross-validation strategy was used: each unit of analysis was left out once, and the linear model was then constructed from scratch using the remaining data.^[@bibr17-1758835920929583]^ This model was then re-applied to the left-out study in order to compare the predicted and observed treatment effect on OS. Based on the linear regression models, a 95% prediction interval was calculated to compare the predicted and observed treatment effect on OS.\
HR, hazard ratio; OS, overall survival; PFS, progression-free survival.](10.1177_1758835920929583-fig3){#fig3-1758835920929583}

Discussion {#section11-1758835920929583}
==========

In the present study, we found that the correlations between DCR/ORR and OS were not strong, indicating that the treatment effect on these two endpoints was not predictive of OS. Notably, we found a strong correlation between PFS and OS (0.72--0.82), irrespective of the applied weighting strategies. Sensitivity analyses that were restricted to the trials with less than 50% crossover, phase III trials and first-line trials further yielded stronger or even nearly perfect correlations (0.83--0.94) between PFS and OS; the leave-one-out cross-validation approach also confirmed that the effects observed on PFS were adequate to predict the treatment effect on OS. Therefore, we propose the use of PFS as the surrogate endpoint for OS in anti-PD-1/PD-L1 trials of metastatic melanoma.

The treatment landscape of metastatic melanoma has dramatically transitioned from cytotoxic agents to targeted drugs and now to anti-PD-1/PD-L1 agents,^[@bibr23-1758835920929583]^ and such changes have translated into enormous survival benefits for melanoma patients with metastatic disease. Recently, the update of survival data from the CheckMate 067 trial reported a 4-year OS rate of 53% in the nivolumab plus ipilimumab group, which is an extravagant expectation for both clinicians and patients 10 years ago. The researchers are now evaluating the potential role of combination regimens, such as PD-1/PD-L1 inhibitors in combination with innate immune stimulants^[@bibr24-1758835920929583]^ or molecularly targeted agents (ClinicalTrials.gov identifiers: NCT02130466, NCT02967692, and NCT02908672), to enhance the therapeutic effect and minimize the risk of toxicities associated with combination therapy. It is well recognized that OS is the standard endpoint for clinical trials; however, several trials have set ORR^[@bibr25-1758835920929583][@bibr26-1758835920929583]--[@bibr27-1758835920929583]^ or PFS^[@bibr5-1758835920929583][@bibr6-1758835920929583]--[@bibr7-1758835920929583],[@bibr18-1758835920929583],[@bibr20-1758835920929583]^ as the primary or coprimary endpoints in anti-PD-1/PD-L1 trials of metastatic melanoma before these endpoints were validated as surrogates for OS. A meta-analysis by Mushti^[@bibr28-1758835920929583]^ reported that the associations between PFS/ORR and OS were too weak to support these RECIST-defined endpoints as surrogates for OS in anti-PD-1/PD-L1 trials of solid tumours. Nonetheless, their analysis was based on 13 positive trials approved by the FDA, which indicated a selection biases in their findings. In addition, the correlation between RECIST-defined endpoints and OS in the melanoma subpopulation was not reported. Our previous study noted a good correlation between PFS and OS in anti-PD-1/PD-L1 trials in metastatic melanoma.^[@bibr29-1758835920929583]^ In the present analysis, we applied more rigorous criteria using three weighting strategies to address this urgent issue, and our findings further validated that correlations between DCR/ORR and OS were not strong. Surprisingly, we identified a strong correlation between PFS and OS, which was further verified through extensive sensitivity analyses and leave-one-out cross-validation. We believe that the robust correlation between PFS and OS in anti-PD-1/PD-L1 therapy of melanoma is mainly attributable to the fact that melanoma is an aggressive tumour and that the subsequent lines of therapy are limited if patients develop progressive disease after anti-PD-1/PD-L1 therapy. Therefore, we propose that in future anti-PD-1/PD-L1 trials for metastatic melanoma, PFS is considered for use as the surrogate endpoint for OS.

STE is an alternative measure for surrogate endpoint validation.^[@bibr16-1758835920929583]^ Using a surrogate endpoint with an STE closer to 1, it would be easier to predict an OS benefit. In the present study, we found that the STE was 0.78 for PFS. In addition, we noted that six of eight comparisons that reported PFS with an upper limit CI for HR \< 0.78 reported improvement in OS, and all the three comparisons that reported PFS with an upper limit CI for HR ⩾ 0.78 failed to report improvement in OS; thus the accuracy rate of an STE of 0.78 was 81.8% (9/11). Therefore, an anti-PD-1/PD-L1 trial in metastatic melanoma producing a hazard reduction of at least 22% (upper 95% CI of HR \< 0.78) for disease progression or death, could expect to promise a statistically significant reduction in OS.

Anti-PD-1/PD-L1 agents exert an antitumour effect by activating effector T cells, resulting in T cells circulating throughout the body that can identify cognate antigens presented by cancer cells.^[@bibr30-1758835920929583]^ Thus, patients who receive anti-PD-1/PD-L1 therapy might develop immune-related response patterns, wherein they initially experience transitory tumour swelling that meets conventional response criteria for progression but is later followed by decreased tumour burden. Beaver and colleagues reported that 14% of patients with metastatic melanoma who continued PD-1 inhibitor treatment beyond RECIST-defined progression experienced delayed tumour decrease and prolonged overall survival,^[@bibr10-1758835920929583]^ indicating the existence of pseudoprogression and a rationale for continuing PD-1 inhibitor treatment for these patients. To distinguish pseudoprogression from truly progressive disease, oncologists modified the conventional RECIST criteria and developed new response criteria, including immune-related response criteria using bidimensional measurements (irRC),^[@bibr31-1758835920929583]^ the revised irRC using unidimensional measurements based on the original RECIST (referred to as irRECIST),^[@bibr32-1758835920929583]^ and now the immune RECIST (iRECIST).^[@bibr33-1758835920929583]^ However, we should bear in mind that the iRECIST requires further validation and that the overall incidence of pseudoprogression in melanoma is low, ranging from 8% to 14%.^[@bibr10-1758835920929583],[@bibr30-1758835920929583],[@bibr34-1758835920929583]^ Therefore, we propose that the RECIST-defined PFS could be set as the primary or coprimary endpoint in anti-PD-1/PD-L1 trials of metastatic melanoma. In addition, we should also set the iRECIST-defined endpoints as the secondary endpoints in future investigations.

Notably, crossover from the control arm to a highly active experimental therapy at the time of progression may result in positive results for PFS but negative results for OS. We observed that half of included trials reported a 23--57% crossover rate, and the sensitivity analysis showed that the inclusion of trials with crossover weakened the correlation between PFS and OS; however, we also recognized that only three comparisons had the crossover rate \>50%, which would reduce the power to make this conclusion. Therefore, with the emergence of anti-PD-1/PD-L1 trials that allow crossover design, the correlation between PFS and OS needs further investigation.

Our study has several notable limitations. First, since the included trials were derived from multiple-line therapy, heterogeneity may exist in our analysis. Hence, we performed a sensitivity analysis that restricted the analysis to trials with first-line therapy and confirmed the very strong correlation between PFS and OS (0.83--0.91). Next, some eligible trials had a small sample size, short follow-up times and phase II designs, accounting for fairly wide confidence intervals of the HR for treatment effects. Thus, the surrogacy of PFS for OS is still not trustworthy in trials with small sample sizes or short follow-up durations, or phase II trials. In addition, the evaluation of PFS in the included studies might be either based on an independent review committee or investigator, which can bias our conclusions. Lastly, our study was performed at the trial level instead of at the individual level.

Conclusion {#section12-1758835920929583}
==========

PFS may be the appropriate surrogate for OS in anti-PD-1/PD-L1 trials of metastatic melanoma. A future similar anti-PD-1/PD-L1 trial would need less than 0.78 for PFS of the upper limit of the confidence interval to predict an OS benefit.
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